Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 14,487

Document Document Title
WO/2020/071664A1
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electr...  
WO/2020/071720A1
The present invention provides: a novel mixture capable of improving the luminous efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.  
WO/2020/071721A1
The present invention provides: a novel mixture which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.  
WO/2020/072695A1
3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an ...  
WO/2020/067657A1
The present invention relates to a composition for an organic optoelectronic element, an organic optoelectronic element and a display device, the composition comprising: a first compound for an organic optoelectronic element, represented...  
WO/2020/064002A1
The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound ...  
WO/2020/063760A1
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.  
WO/2020/065048A1
The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH ...  
WO/2020/065613A1
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL ...  
WO/2020/067455A1
The objective of the present invention is to provide a compound which may be useful for preventing or treating constipation or the like. The present invention provides a compound represented by formula (I) [each symbol in the formula is ...  
WO/2020/061046A1
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions,...  
WO/2019/118411A3
The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizin...  
WO/2020/041405A8
The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating ...  
WO/2020/041406A8
The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating ...  
WO/2020/060286A1
The present invention provides a novel heterocyclic compound and an organic light emitting device using same.  
WO/2020/060268A1
The present invention relates to: a novel sulfonamide derivative with a fused pyrimidine skeleton, represented by chemical formula I; a solvate thereof or pharmaceutically acceptable salts thereof; and a pharmaceutical composition contai...  
WO/2020/055672A1
Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, whic...  
WO/2020/054657A1
To provide a compound for selectively inhibiting Nav1.7 rather than Nav1.5. A heteroaromatic amide derivative or a salt thereof which is highly effective for pain and various other Nav1.7-related diseases, the heteroaromatic amide deriva...  
WO/2020/054670A1
To provide a compound for selectively inhibiting Nav1.7 rather than Nav1.5. A heteroaromatic amide derivative or a salt thereof which is highly effective for pain and various other Nav1.7-related diseases, the heteroaromatic amide deriva...  
WO/2020/055113A1
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...  
WO/2020/048548A1
Disclosed are a series of tricyclic compounds, and use thereof in the preparation of medicaments for treating diseases related to CRBN proteins. In particular, disclosed are derivative compounds represented by formula (I) or pharmaceutic...  
WO/2020/048904A1
The invention provides new bicyclic heteroaryl compounds having the general formula (I) wherein R1, Ar, n and m are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using ...  
WO/2020/048826A1
The present invention covers 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (I-a), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermed...  
WO/2020/050546A1
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...  
WO/2020/050409A1
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1,...  
WO/2020/047424A1
The present invention provides commercial processes for preparing 2- ((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-l-((S)-l-( isopropylsulfonyl)-3-methylbutan-2-yl)-3 -m ethyl-2-oxopiperi din-3 -yl)acetic acid as well as intermediate...  
WO/2020/047241A1
The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h exahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin- 8-yl)-butan-1-one or 1-(4-fluoro-phe...  
WO/2020/012408A3
The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts thereof.  
WO/2020/038387A1
A compound of formula (I) and a pharmaceutical composition thereof, and a method for using the compound of formula (I) for the prevention and/or treatment of immune-related diseases. (I)  
WO/2020/041405A1
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...  
WO/2020/041406A1
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...  
WO/2020/036946A1
Provided are compounds of Formula (I'), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and prod...  
WO/2020/035425A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using t...  
WO/2020/035424A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...  
WO/2020/030925A1
The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.  
WO/2020/020267A1
The present invention provides a deutero-substituted polycyclic pyridone compound and a prodrug thereof, and a composition containing the compound, and use thereof. The deutero-substituted polycyclic pyridone compound is a compound repre...  
WO/2020/022237A1
The present invention relates to a therapeutic agent for neuropsychiatric disorders containing a compound represented by formula (1) or a pharmaceutically acceptable salt thereof an active ingredient.  
WO/2020/021252A1
Novel compounds of formulae (l)-(lll) are provided, as well as pharmaceutical compositions comprising the novel compounds. Also described are therapeutic uses of the novel compounds, in particular in relation to the treatment of infectio...  
WO/2020/020377A1
A compound represented by formula I or a pharmaceutically acceptable salt thereof and a use thereof in preparing a drug for treating, stopping, or preventing a disease or disorder mediated by FGFR4 activity.  
WO/2020/020800A1
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of ...  
WO/2020/023551A1
Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also ...  
WO/2020/023560A1
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...  
WO/2020/018970A1
The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLR...  
WO/2020/016710A1
The present invention provides, in part, a compound selected from the group consisting of: 1,1,1,3,3,3-hexafluoropropan-2-yl (3R)-3-{[(cyclopropylmethyl)sulfonyl]amino}-1-oxa-8-azaspiro [4.5]decane-8-carboxylate; 1,1,1,3,3,3-hexafluoropr...  
WO/2020/017624A1
To provide an anticancer agent comprising, as an active ingredient, a derivative that has a tumor proliferation inhibitory effect equivalent to or exceeding that of telomestatin, can be synthesized on a mass scale and has a high chemical...  
WO/2020/018975A1
The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activat...  
WO/2020/017569A1
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate...  
WO/2020/012408A2
The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts thereof.  
WO/2020/009374A1
The present invention relates to a 4-substituted oxazoloquinolinone derivative, and a compound, which is a salt of the derivative, that show effects of preventing and treating allergic diseases, such as asthma or atopic dermatitis, by co...  
WO/2020/009179A1
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, s...  

Matches 151 - 200 out of 14,487